The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Outcome Measures, 2022Development of Standardized Measurements for Monitoring the Progression of Parkinson’s Disease via MRI
Study Rationale: One of the difficulties in research towards new treatments in Parkinson’s disease (PD) is the diversity of disease presentations and the lack of tools to measure the effect of a...
-
, 2022Studying the Epidemiology of Parkinson’s Disease in Latin America: Learning from Underrepresented Populations
Study Rationale: Initial evidence has shown that the global distribution of Parkinson’s disease (PD) may vary; however, little is known about the prevalence of PD across large parts of the world. This...
-
Diversity, Equity and Inclusivity in Parkinson's research, 2022Risk Factors for Parkinson’s Disease Among Participants in the Black Women’s Health Study
Study Rationale: Little is known about the incidence, clinical presentation and risk factors for Parkinson’s disease (PD) in Black women, yet the existing evidence suggest that they may have a worse...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Using “Nanobodies” to Prevent Formation of Intracellular Alpha-synuclein Aggregates
Study Rationale: The aggregation of a structurally abnormal form of the protein alpha-synuclein appears to be responsible for the initiation and progression of Parkinson’s disease (PD). In previous...
-
Alpha-synuclein Seed Amplification Assay Program, 2022Development of a Reliable Diagnostic Test for Parkinson’s Disease Using Patient Blood Samples
Study Rationale: Although diagnosis of Parkinson’s disease (PD) is crucial for the success of treatment, especially in the early stages, there are still no biomarkers available for use as a reliable...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Inhibiting Lrrk2 Specifically in the Brain
Study Rationale: Neurodegenerative disorders such as Parkinson’s disease (PD) affect the brain. Some of the drugs designed to treat PD have unwanted side effects in the rest of the body. To minimize...
![Two female doctors talking in the lab.](/sites/default/files/styles/ad_callout_single/public/images/ad/apply-for-grant-404-Large-Image-Callout-A-1.jpg?h=2a1ad497&itok=-_5jZ5iX)
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.